The company leverages artificial intelligence to screen for liver and kidney disease, as well as other chronic conditions that cause progressive organ damage. The company has plans to penetrate new markets and serve patients and physicians directly and through strategic partnerships. Fibronostics is a global diagnostics company, providing non-invasive, algorithmic diagnostics and insights to detect and manage organ lesions caused by metabolic diseases.